Skip to main content
Top
Published in: Journal of Inflammation 1/2020

01-12-2020 | Septicemia | Research

Different signaling pathways involved in the anti-inflammatory effects of unfractionated heparin on lipopolysaccharide-stimulated human endothelial cells

Authors: Xu Li, Lu Li, Yuequan Shi, Sihan Yu, Xiaochun Ma

Published in: Journal of Inflammation | Issue 1/2020

Login to get access

Abstract

Background

There is a complex interplay between inflammatory response and coagulation in sepsis. Heparin is used as a recognized anticoagulant and possesses multiple biological properties that possibly affect sepsis. This study aimed to determine the possible signaling pathways involved in the anti-inflammatory effects of unfractionated heparin (UFH) on lipopolysaccharide (LPS)-stimulated human pulmonary microvascular endothelial cells (HPMECs).

Methods

HPMECs were transfected with siRNA targeting IκB-α. Cells were treated with UFH (0.01 U/ml~ 10 U/ml) 15 min before adding LPS (10 μg/ml). We detected the markers of systemic inflammatory response. Release of interleukin (IL)-6, IL-8 were evaluated at 3 h by ELISA and at 1 h by qRT-PCR. After 1 h, nuclear factor-κB (NF-κB) as well as phosphorylated inhibitor κB-α (IκB-α), signal transducer and activator of transcription-3 (STAT3) and ERK1/2, JNK, p38 mitogen-activated protein kinase (MAPK) expressions were evaluated by Western blot. DNA binding was conducted to further prove the activation of NF-κB pathway.

Results

In HPMECs, UFH obviously inhibited LPS-stimulated production of IL-6 and IL-8, especially in 10 U/ml. UFH inhibited LPS-induced phosphorylation of IκB-α, ERK1/2, JNK, p38 MAPK and STAT3. UFH also suppressed LPS-stimulated nuclear translocation of NF-κB. Importantly, transfection with siRNA targeting IκB-α induced more obvious inflammatory response. UFH suppressed cytokines production and phosphorylation of different signaling pathways in IκB-α silencing cells.

Conclusion

These results demonstrate that UFH exerts the anti-inflammatory effects on LPS-stimulated HPMECs by different signaling pathways.
Literature
1.
go back to reference Iba T, Levy JH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost. 2018;16(2):231–41.CrossRef Iba T, Levy JH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost. 2018;16(2):231–41.CrossRef
2.
go back to reference Opal SM, van der Poll T. Endothelial barrier dysfunction in septic shock. J Intern Med. 2015;277(3):277–93.CrossRef Opal SM, van der Poll T. Endothelial barrier dysfunction in septic shock. J Intern Med. 2015;277(3):277–93.CrossRef
3.
go back to reference Levi M, Van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004;109:2698–704.CrossRef Levi M, Van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004;109:2698–704.CrossRef
4.
go back to reference Onishi A, St Ange K, Dordick JS, Linhardt RJ. Heparin and anticoagulation. Front Biosci (Landmark Ed). 2016;21:1372–92.CrossRef Onishi A, St Ange K, Dordick JS, Linhardt RJ. Heparin and anticoagulation. Front Biosci (Landmark Ed). 2016;21:1372–92.CrossRef
5.
go back to reference Ludwig RJ. Therapeutic use of heparin beyond anticoagulation. Curr Drug Discov Technol. 2009;6:281–9.CrossRef Ludwig RJ. Therapeutic use of heparin beyond anticoagulation. Curr Drug Discov Technol. 2009;6:281–9.CrossRef
6.
go back to reference Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res. 2008;122:743–52.CrossRef Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res. 2008;122:743–52.CrossRef
7.
go back to reference Li X, Ma X. The role of heparin in sepsis: much more than just an anticoagulant. Br J Haematol. 2017;179(3):389–98.CrossRef Li X, Ma X. The role of heparin in sepsis: much more than just an anticoagulant. Br J Haematol. 2017;179(3):389–98.CrossRef
8.
go back to reference Li X, Zheng Z, Li X, Ma XC. Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-κB activation on endothelial cell. Cytokine. 2012;60:114–21.CrossRef Li X, Zheng Z, Li X, Ma XC. Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-κB activation on endothelial cell. Cytokine. 2012;60:114–21.CrossRef
9.
go back to reference Li X, Li X, Zheng Z, Ma XC. Unfractionated heparin suppresses lipopolysaccharide-induced monocyte chemoattractant protein-1 expression in human microvascular endothelial cells by blocking Krüppel-like factor 5 and nuclear factor-κB pathway. Immunobiology. 2014;219:778–85.CrossRef Li X, Li X, Zheng Z, Ma XC. Unfractionated heparin suppresses lipopolysaccharide-induced monocyte chemoattractant protein-1 expression in human microvascular endothelial cells by blocking Krüppel-like factor 5 and nuclear factor-κB pathway. Immunobiology. 2014;219:778–85.CrossRef
10.
go back to reference Li X, Liu YN, Wang L, Li ZL, Ma XC. Unfractionated heparin attenuates LPS-induced IL-8 secretion via PI3K/Akt/NF-κB signaling pathway in human endothelial cells. Immunobiology. 2015;220:399–405.CrossRef Li X, Liu YN, Wang L, Li ZL, Ma XC. Unfractionated heparin attenuates LPS-induced IL-8 secretion via PI3K/Akt/NF-κB signaling pathway in human endothelial cells. Immunobiology. 2015;220:399–405.CrossRef
11.
go back to reference Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G, Nishigaki I. The vascular endothelium and human diseases. Int J Biol Sci. 2013;9(10):1057–69.CrossRef Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G, Nishigaki I. The vascular endothelium and human diseases. Int J Biol Sci. 2013;9(10):1057–69.CrossRef
12.
go back to reference Ince C, Mayeux PR, Nguyen T, Gomez H, Kellum JA, Ospina-Tascón GA, Hernandez G, Murray P, De Backer D, ADQI XIV Workgroup. The endothelium in sepsis. Shock. 2016;45(3):259–70.CrossRef Ince C, Mayeux PR, Nguyen T, Gomez H, Kellum JA, Ospina-Tascón GA, Hernandez G, Murray P, De Backer D, ADQI XIV Workgroup. The endothelium in sepsis. Shock. 2016;45(3):259–70.CrossRef
14.
go back to reference Cinel I, Dellinger RP. Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis. 2007;20:345–52.CrossRef Cinel I, Dellinger RP. Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis. 2007;20:345–52.CrossRef
15.
go back to reference Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003;101:3765–77.CrossRef Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003;101:3765–77.CrossRef
16.
go back to reference Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1:135–45.CrossRef Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1:135–45.CrossRef
17.
go back to reference Li X, Li ZL, Zheng Z, Liu YN, Ma XC. Unfractionated heparin ameliorates lipopolysaccharide-induced lung inflammation by downregulating nuclear factor-κB signaling pathway. Inflammation. 2013;36:1201–8.CrossRef Li X, Li ZL, Zheng Z, Liu YN, Ma XC. Unfractionated heparin ameliorates lipopolysaccharide-induced lung inflammation by downregulating nuclear factor-κB signaling pathway. Inflammation. 2013;36:1201–8.CrossRef
18.
go back to reference Zhao DM, Ding RY, Mao YR, et al. Heparin rescues sepsis-associated acute lung injury and lethality through the suppression of inflammatory responses. Inflammation. 2012;35(6):1825–32.CrossRef Zhao DM, Ding RY, Mao YR, et al. Heparin rescues sepsis-associated acute lung injury and lethality through the suppression of inflammatory responses. Inflammation. 2012;35(6):1825–32.CrossRef
19.
go back to reference Chen S, Zhang XJ, Sun YN, et al. Unfractionated heparin attenuates intestinal injury in mouse model of sepsis by inhibiting heparanase. Int J Clin Exp Pathol. 2015;8(5):4903–12.PubMedPubMedCentral Chen S, Zhang XJ, Sun YN, et al. Unfractionated heparin attenuates intestinal injury in mouse model of sepsis by inhibiting heparanase. Int J Clin Exp Pathol. 2015;8(5):4903–12.PubMedPubMedCentral
20.
go back to reference Farwell SL, Kanyi D, Hamel M, Slee JB, Miller EA, Cipolle MD, Lowe-Krentz LJ. Heparin decreases in tumor necrosis factor α (TNFα)-induced endothelial stress responses require Transmembrane protein 184A and induction of dual specificity phosphatase 1. J Biol Chem. 2016;291(10):5342–54.CrossRef Farwell SL, Kanyi D, Hamel M, Slee JB, Miller EA, Cipolle MD, Lowe-Krentz LJ. Heparin decreases in tumor necrosis factor α (TNFα)-induced endothelial stress responses require Transmembrane protein 184A and induction of dual specificity phosphatase 1. J Biol Chem. 2016;291(10):5342–54.CrossRef
21.
go back to reference Anastase-Ravion S, Blondin C, Cholley B, Haeffner-Cavaillon N, Castellot JJ, Letourneur D. Heparin inhibits lipopolysaccharide (LPS) binding to leukocytes and LPS-induced cytokine production. J Biomed Mater Res A. 2003;66(2):376–84.CrossRef Anastase-Ravion S, Blondin C, Cholley B, Haeffner-Cavaillon N, Castellot JJ, Letourneur D. Heparin inhibits lipopolysaccharide (LPS) binding to leukocytes and LPS-induced cytokine production. J Biomed Mater Res A. 2003;66(2):376–84.CrossRef
22.
go back to reference Li X, Liu YN, Ma XC. Unfractionated heparin inhibits lipopolysaccharide-induced expression of granulocyte colony-stimulating factor in human endothelial cells through Toll-like receptor 4 signaling pathway. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015;27(2):81–5.PubMed Li X, Liu YN, Ma XC. Unfractionated heparin inhibits lipopolysaccharide-induced expression of granulocyte colony-stimulating factor in human endothelial cells through Toll-like receptor 4 signaling pathway. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015;27(2):81–5.PubMed
Metadata
Title
Different signaling pathways involved in the anti-inflammatory effects of unfractionated heparin on lipopolysaccharide-stimulated human endothelial cells
Authors
Xu Li
Lu Li
Yuequan Shi
Sihan Yu
Xiaochun Ma
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2020
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/s12950-020-0238-7

Other articles of this Issue 1/2020

Journal of Inflammation 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.